ALDX — Aldeyra The
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 9
- Website: https://www.aldeyra.com
Latest SEC filings for ALDX
- 8-K — 2026-09-29
- SCHEDULE 13G — 2026-08-12
- 10-Q — 2026-08-06
- 8-K — 2026-07-30
- 8-K — 2026-07-15
- 8-K — 2026-06-10
- 10-Q — 2026-05-07
- ARS — 2026-04-27
- 8-K — 2026-04-20
- 8-K — 2026-04-01
Latest ALDX news
- — RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week (Zacks Investment Research)
- — Here's Why You Should Add ANRO Stock to Your Portfolio Now (Zacks Investment Research)
- — Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal (Zacks Investment Research)
- — Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why (Zacks Investment Research)
- — PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know (Zacks Investment Research)
- — argenx Meets Primary Endpoint in Phase II Celiac Disease Study (Zacks Investment Research)
- — EDIT Set to Begin First-in-Human Study in Hypercholesterolemia (Zacks Investment Research)
- — Here's Why You Should Add LPCN Stock to Your Portfolio Now (Zacks Investment Research)
- — Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash (Zacks Investment Research)
- — ETON Stock Surges 108% in Six Months: Here's What You Need to Know (Zacks Investment Research)
Educational tool only — not investment advice.